Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform

BACKGROUND: Breast cancer is the most common invasive cancer among women. Currently, there are only a few models used for therapy selection, and they are often poor predictors of therapeutic response or take months to set up and assay. In this report, we introduce a microfluidic OrganoPlate® platfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanz, Henriette L., Saleh, Anthony, Kramer, Bart, Cairns, Junmei, Ng, Chee Ping, Yu, Jia, Trietsch, Sebastiaan J., Hankemeier, Thomas, Joore, Jos, Vulto, Paul, Weinshilboum, Richard, Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668957/
https://www.ncbi.nlm.nih.gov/pubmed/29096610
http://dx.doi.org/10.1186/s12885-017-3709-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668957/
https://www.ncbi.nlm.nih.gov/pubmed/29096610
http://dx.doi.org/10.1186/s12885-017-3709-3

Ejemplares similares